News | October 21, 2023
Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
